{
    "clinical_study": {
        "@rank": "30066", 
        "acronym": "CATACHOC", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "saline administration over 24 h following full optimization of patient according to current guidelines"
            }, 
            {
                "arm_group_label": "clonidine", 
                "arm_group_type": "Active Comparator", 
                "description": "clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines"
            }
        ], 
        "brief_summary": {
            "textblock": "The hallmarks of septic shock are hypovolemia and reduced pressor response to endogenous\n      noradrenaline. The working hypothesis is that the higher the plasma concentration of\n      endogenous noradrenaline will be, the lower the pressor response to exogenous noradrenaline\n      will be. This will be tested in patients presenting with septic shock, following state of\n      the art management (including repeated assessment of vena cava diameter and compliance, and\n      response to dynamic indices of loading) following placebo vs clonidine administration (1\n      mcg.kg-1.h-1 over 24 h without bolus) and administration of increasing doses of\n      noradrenaline (1 mcg, 2 mcg, etc. up to a delta systolic blood pressure circa 25-30 mm Hg)."
        }, 
        "brief_title": "Upregulation of Alpha-1 Receptors Upon Septic Shock?", 
        "condition": "Septic Shock", 
        "condition_browse": {
            "mesh_term": [
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients presenting to the CCU with septic shock : SBP<90 mm Hg refractory to volume\n             load (>30 ml.kg-1 within 6 h before inclusion) thus in need administration of\n             noradrenaline for >1 h (0.1 mcg.kg-1.h-1 i.e. >0.5 mg.h-1/70 kg) to maintain mean\n             BP>65 mm Hg.\n\n          -  criteria for sepsis :temperature>38.5 or <36\u00b0C ; WBC>12 000 or <4000/ml ; tachypnea\n             (>20 cycles par min) or mechanical ventilation ; tachycardia : >90 bpmin\n\n          -  written informed consent by the patient or next of kin or signature by the\n             investigators of the form \"emergency inclusion\"\n\n        Exclusion Criteria:\n\n          -  age<18 ans\n\n          -  pregnancy\n\n          -  mental illness making informed consent impossible\n\n          -  Absence of consent as signed by the patient or next of kin or signature of \"emergency\n             inclusion form\"\n\n          -  individual without social security coverage or participating in another biomedical\n             research\n\n          -  Contre-indications to  clonidine (uncorrected hypovolemia, sick sinus syndrom, III\n             grade AV block)\n\n          -  HR<70 bp/min\n\n          -  pre-exitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856517", 
            "org_study_id": "2011PPRC01TURC"
        }, 
        "intervention": [
            {
                "arm_group_label": "clonidine", 
                "intervention_name": "Clonidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clonidine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pressor response", 
            "chronotropic response"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "contact": {
                "email": "eric.dardare@gmail.com", 
                "last_name": "Eric Dardare, MD", 
                "phone": "33 4 72 36 67 43"
            }, 
            "facility": {
                "address": {
                    "city": "Lyon", 
                    "country": "France", 
                    "zip": "69275"
                }, 
                "name": "Critical Care Unit, Hopital Desgenettes"
            }, 
            "investigator": [
                {
                    "last_name": "Eric Dardare, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Luc Quintin, MD PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Up Regulation of Alpha-1 Receptors Upon Septic Shock ?", 
        "overall_contact": {
            "email": "eric.dardare@gmail.com", 
            "last_name": "Eric Dardare, MD", 
            "phone": "33 4 72 36 67 43"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "bolus of exogenous noradrenaline (1 mcg and up) are administered to the patient to evoke an  increase in delta systolic blood pressure by 25-30 mm Hg. Administration of increasing dose of noradrenaline is stopped as soon as delta systolic blood pressure has reached 25-30 mm Hg.", 
            "measure": "change in pressor response to exogenous noradrenaline", 
            "safety_issue": "No", 
            "time_frame": "0 and 24 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856517"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es", 
            "investigator_full_name": "Eric Dardare", 
            "investigator_title": "MD attending physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "change in heart rate response to increasing doses of dobutamine (100 mcg and up) to evoke an increase in heart rate up to 20 beats per min.", 
            "safety_issue": "No", 
            "time_frame": "0 and 24 h"
        }, 
        "source": "Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}